Nursing Elites

1. What is a condition where a blood clot forms in a deep vein, usually in the legs, and can lead to serious complications if it travels to the lungs?

• A. Deep vein thrombosis (DVT)
• B. Pulmonary embolism
• C. Varicose veins
• D. Raynaud's disease

Correct answer: A

Rationale: The correct answer is A, Deep vein thrombosis (DVT). Deep vein thrombosis occurs when a blood clot forms in a deep vein, usually in the legs. If the clot dislodges and travels to the lungs, it can lead to a serious condition called a pulmonary embolism. Choice B, pulmonary embolism, is incorrect as it is the consequence of a DVT clot traveling to the lungs, not the initial condition. Choices C and D, varicose veins, and Raynaud's disease, respectively, are unrelated conditions to the formation of blood clots in deep veins.

2. What is the term for a blood clot blocking an artery in the lungs, leading to symptoms like shortness of breath and chest pain?

• A. Pulmonary embolism
• B. Deep vein thrombosis (DVT)
• C. Myocardial infarction
• D. Pneumothorax

Correct answer: A

Rationale: The correct answer is A, pulmonary embolism. A pulmonary embolism occurs when a blood clot travels to the lungs and blocks an artery, causing symptoms like shortness of breath and chest pain. Choice B, deep vein thrombosis (DVT), involves a blood clot forming in a deep vein, usually in the legs. Choice C, myocardial infarction, refers to a heart attack due to blocked blood flow to the heart muscle. Choice D, pneumothorax, is a collapsed lung due to air leaking into the chest cavity.

3. The client on spironolactone should avoid which of the following?

• A. Foods high in potassium
• B. Foods high in sodium
• C. Foods high in calcium
• D. Foods high in chloride

Correct answer: A

Rationale: The correct answer is A: Foods high in potassium. Spironolactone is a potassium-sparing diuretic, meaning it helps the body retain potassium and excrete sodium. Consuming foods high in potassium while on spironolactone can lead to an excess of potassium in the body, potentially causing hyperkalemia. Choices B, C, and D are incorrect because spironolactone does not directly interact with sodium, calcium, or chloride in a way that would require specific dietary restrictions related to these minerals.

4. The client on warfarin has an INR of 1.2. What is the nurse’s priority action?

• A. Increase the dose of warfarin
• B. Administer vitamin K
• C. Monitor for signs of bleeding
• D. Hold the next dose and notify the healthcare provider

Correct answer: A

Rationale: The correct answer is to increase the dose of warfarin. An INR of 1.2 is below the therapeutic range for a client on warfarin, indicating that the dose is subtherapeutic. The priority action in this situation is to adjust the dose to achieve the target therapeutic INR range (usually 2-3) to prevent thromboembolic events. Administering vitamin K is not necessary as the INR is low, and there are no signs of bleeding. Monitoring for signs of bleeding is important but not the priority in this case since the INR is subtherapeutic. Holding the next dose and notifying the healthcare provider would delay the intervention needed to adjust the dose and achieve the therapeutic range.

5. Which condition is characterized by the lungs becoming scarred and stiff, leading to difficulty breathing and inadequate oxygen intake into the bloodstream?

• A. Pulmonary fibrosis
• B. Cystic fibrosis
• C. COPD
• D. Tuberculosis

Correct answer: A

Rationale: The correct answer is A, Pulmonary fibrosis. Pulmonary fibrosis is a lung disease where lung tissue is damaged and scarred, resulting in breathing difficulties and decreased oxygen transfer into the bloodstream. Cystic fibrosis (B) is a genetic disorder primarily affecting the lungs and digestive system, not causing lung scarring. COPD (C) includes conditions like chronic bronchitis and emphysema but doesn't specifically involve lung scarring. Tuberculosis (D) is a bacterial infection that primarily affects the lungs but doesn't cause lung tissue scarring and stiffness as seen in pulmonary fibrosis.

Similar Questions